Pylum Biosciences

Pylum Biosciences is a company developing the Avidocin platform technology capable of generating bactericidal protein complexes targeting specific bacterial pathogens. It provides Avidocin agents targeting human pathogens such as C. difficile, uropathogenic E. coli, and K. pneumoniae. Avidocin proteins can be used in applications where traditional antibiotics are ineffective, contraindicated, or are being phased out of the market, such as preventing C. difficile infections (CDIs), managing the microbiota, food safety, and animal health.